Deals

News We’re Watching: FDA Recalls Communication Pilot; Cardinal Buys Two Firms; Medtronic Diabetes App Cleared

This week, the US device center announced a pilot program to speed communications about high-risk recalls; Cardinal paid $3.9B for Advanced Diabetes Supply Group and GIA Alliance; a companion diagnostic for Merck lung cancer drug Tepmetko got FDA clearance; and more.

News We’re Watching: Medicare Payments For Renal Denervation; Acquisitions for Tempus And Boston Sci; LumiThera And Caris Land FDA Authorizations

 

This week, renal denervation systems from Medtronic and Recor won Medicare coverage; Boston Scientific bought cardiac-mapping firm Cortex; Veravas and Phanes Biotech teamed up on an Alzheimer’s diagnostic; and more.

Beta Bionics Launches iLet Bionic Pancreas With Abbott’s Latest-Generation CGM

 
• By 

Beta Bionics’ automated insulin delivery system is now pairable with Abbott’s FreeStyle Libre 3 Plus CGM.

What's Next For Abbott Diabetes?

 
• By 

Abbott’s Diabetes Care Division has recorded meteoric growth over recent years. Partnerships and a laser-focused strategy for driving patient access are at the core of its success, says Chris Scoggins, SVP of commercial operations and marketing.


News We’re Watching: Hologic Buys Gynesonics, Novocure Cancer Treatment Gets FDA Approval, New IMDRF Members

 

This week, Hologic announced it would pay $350m for uterine fibroid treatment firm Gynesonics; the US FDA authorized a Novocure cancer treatment and a surgical robot from CMR Surgical; and the IMDRF announced 15 new members.

Deals Shaping The Medtech And Diagnostics Industries, September 2024

 
• By 

An interactive look at medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.

LSX Nordic 2024: Strategics Offer Tips On Landing A Partnership Or Acquisition

 
• By 

At this year’s LSX Nordic conference, experts from Baxter, Philips and Novo Nordisk described key attributes they look for when selecting companies for partnerships or acquisitions and provided advice to founders on how and when to start positioning their start-ups for such opportunities.

News We’re Watching: J&J Buys V-Wave, Procept Plans Aquablation Trial, TriClip Up For Medicare Coverage

 

This week, J&J announced that it was buying heart failure device firm V-Wave; Procept got the FDA’s OK on a clinical trial of its Aquablation treatment for prostate cancer; and CMS began to consider Medicare reimbursement of Abbott’s TriClip tricuspid repair device.


Owkin Teams With AstraZeneca To Develop AI-Based Breast Cancer Prescreening Tool

 

Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.

News We’re Watching: New OPEQ Head, Constructive Bio Funding Round, Natera Wins Injunction In Patent Suit

This week, the FDA announced a new head of its device evaluation office; synthetic genomics firm Constructive Bio landed $58m in funding; and Natera got a permanent injuction against NeoGenomics Labs' RaDaR assay.

Tobacco Giant Philip Morris Sells Medical Device Business, Keeps Consumer Health Footprint

 
• By 

Philip Morris described a scenario of being essentially blacklisted by the health care sector and its CDMO partners as it threw in the towel on its £1.1bn acquisition of UK inhalation specialist Vectura. It agreed to offload the firm at a fraction of the initial cost.

Medtronic Partners With Siemens Healthineers To Evolve AiBLE Spine Surgery Platform

 
• By 

The companies intend to co-market Siemens Healthineers’ Multitom Rax as part of Medtronic’s AiBLE ecosystem, which combines advanced technologies in navigation, robotics, imaging, data analytics, and AI to enhance the precision and predictability of spine and cranial surgeries.


Biocomposites Fully Acquires SYNICEM And Subiton Lines, Launches NanoBone In UK

 

UK-based Biocomposites will begin selling in the UK its next-generation osteoinductive bone graft substitute, NanoBone, which came with its acquisition of Artoss GmbH in June 2023. Meanwhile, the company has purchased remaining shares in the manufacturers of SYNICEM and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers.

J&J Versus Auris: Robotics Fallout With Big Implications For M&A

 

J&J’s “pants down” moment with Auris could permanently change how medtech M&A is conducted. Build-to-buy arrangements, which leave companies’ destinies in the hands of their owners, are likely to replace current earn-out models.

US Eroxon Launch In October Will Mark Haleon’s First Foray Into Sexual Health

 
• By 

Haleon will launch Futura Medical's FDA-approved OTC medical device for erectile dysfunction in the US before the end of the year. Already available to pre-order online on Amazon, Eroxon represents the firm's first move into the sexual health category. 

German, California Firms Offer Digital Access To Mental Health Content For Menstrual Cycle, Fertility

 

Clue Plus members will have access to 50% off a Headspace subscription for tailored guidance, support and validation to help manage cycle-related stress and improve overall well-being.


Deals Shaping The Medtech And Diagnostics Industries, August 2024

 
• By 

An interactive look at medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.

Deals Shaping The Medtech And Diagnostics Industries, July 2024

 
• By 

An interactive look at medtech and diagnostics deals made during July 2024. Data courtesy of Biomedtracker.

BD Sees Bright Future For Edwards’ Critical Care, Now BD Advanced Patient Monitoring

 

Edwards Lifesciences’ Critical Care business “invented the hemodynamic monitoring category, and its solutions are currently used in more than 10,000 hospitals globally to better understand the cardiovascular condition in real-time for critically ill patients, which helps improve outcomes,” says BD, which sees synergies and new innovation opportunities across the groups’ data sets and platforms. Acquired for $4.2bn cash, Critical Care generated more than $900m in revenue in 2023.

News We’re Watching: $1B Judgement Against J&J Recalls For Abbott, Baxter, More; Karl Storz Announces Fujifilm Partnership

 

This week, a Delaware court awarded Auris Health shareholders $1bn in a lawsuit against Johnson & Johnson; Abbott recalled some FreeStyle Libre 3 sensors; and McKesson purchased a controlling interest in a Florida cancer care chain.